Regenerative medicine company Orthocell Ltd (ASX:OCC, OTC:ORHHF) will host an investor webinar on Monday, February 2, 2026, to provide an operational update, including the status of the US roll-out of Remplir™.
The webinar will be presented by chairman John Van Der Wielen and chief executive officer and managing director Paul Anderson.
Investor Briefing – Webinar
When: 8.00am AWST | 11.00am AEDST, Monday, February 2, 2026
Register: https://us02web.zoom.us/webinar/register/WN_Bzb_fueGS7eOekqa6xwU1A
Following registration, participants will receive a confirmation email with webinar access details.
Orthocell posts seventh straight record quarter as US Remplir sales gain traction
Orthocell delivered a seventh consecutive quarter of record revenue, reporting $3.2 million in sales for the December 2025 quarter as early momentum builds for its US nerve repair product Remplir.
The result was up 45% on the prior corresponding period and 7% above the previous quarterly record, extending a run of consistent growth the company said reflects increasing adoption across established and emerging markets.
Read more: Orthocell posts seventh straight record quarter as US Remplir rollout gains traction
Orthocell said the revenue lift was driven mainly by deeper penetration of Remplir in existing markets, alongside early contributions from the US following mid-2025 clearance.
US sales totalled $90,000 in December alone, which the company characterised as the start of a longer-term uplift from a market it estimates at US$1.6 billion. Orthocell also reported recording its first 100 US sales during the quarter.
Across the past seven quarters, Orthocell said it has achieved a compound quarterly growth rate of 10.4%, supported by rising surgeon adoption of Remplir and ongoing sales of its dental membrane product Striate+.